Legend Biotech Corporation (LEGN)
| Previous Close | 44.38 |
| Open | 44.83 |
| Bid | 45.48 x 100 |
| Ask | 45.64 x 100 |
| Day's Range | 44.65 - 45.64 |
| 52 Week Range | 42.08 - 77.32 |
| Volume | |
| Avg. Volume | 1,023,421 |
| Market Cap | 8.319B |
| Beta (5Y Monthly) | 0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
SOMERSET, N.J., May 13, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2024 unaudited financial results and key corporate highlights.
- Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
SOMERSET, N.J., April 22, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that the European Commission (EC) has granted approval of CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), have demonstrated disease progression on
- Business Wire
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
SOMERSET, N.J., April 11, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.
